Mirror Biologics, Inc.

Mirror Biologics is a clinical-stage, international biopharmaceutical company developing an 'off-the-shelf' class of immunotherapy built on living, non-genetically-manipulated immune cells. Its patented Mirror Effect platform - protected by more than 200 issued patents - powers a pipeline led by AlloStim for cancer, AlloPrime as a universal anti-viral vaccine for the elderly, and StimVax as a neoantigen vaccine. Headquartered in Tampa, Florida with GMP manufacturing in Jerusalem and clinical operations across Thailand and Malaysia, the company is advancing AlloStim into late-stage trials, including a Phase II metastatic colorectal cancer study run in collaboration with Merck KGaA.